Astrotech 21.64M share Spot Secondary priced at $1.50 » 06:1404/0804/08/21
The deal size was…
The deal size was increased to 21.6M shares from 6.7M shares. H.C. Wainwright acted as sole book running manager for the offering.
Astrotech announces $10M bought deal offering of common stock » 16:4804/0704/07/21
Astrotech Corporation announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 6.67M shares of common stock of the company at a price to the public of $1.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about April 12, subject to satisfaction of customary closing conditions. Astrotech intends to use the net proceeds of the offering for general corporate purposes, working capital, and capital expenditures. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
Astrotech and Cleveland Clinic in pact for breath analysis rapid Covid test » 08:1504/0704/07/21
Astrotech subsidiary, BreathTech Corporation announced that it has signed an Investigator-Initiated Study Agreement with the Cleveland Clinic Foundation Under this agreement, BreathTech's BreathTest-1000( will be used to compare exhaled breath from individuals who have tested positive on a COVID-19 polymerase chain reaction test with that from subjects who have had a negative COVID-19 PCR test. The goal of the pilot study will be to analyze different volatile organic compounds rom the breath to evaluate the correlation with different disease states. "This protocol aims to build and expand on our ongoing expertise in the area of breath testing, applying the technology to COVID-19," said Raed Dweik, MD, Chairman of Cleveland Clinic's Respiratory Institute. "The ability to detect viral diseases, such as COVID-19, in breath may allow for early detection of illness prior to symptom onset. The purpose of this study is to determine if COVID-19 can be diagnosed by analysis of volatile compounds in a patient's breath." Cleveland Clinic and BreathTech Corporation entered into a joint development and option agreement for the BreathTech technology. Dr. Dweik is an inventor of this technology. Dr. Dweik and Cleveland Clinic may benefit financially if this research is successful. Dr. Dweik and his research team were some of the first to identify that unique VOC metabolites in the breath can be used to detect certain diseases.
|Over a week ago|
Astrotech unit enters deal with Sanmina to mass produce spectrometry products » 16:0103/3003/30/21
Astrotech announced that…
Astrotech announced that its Astrotech Technologies, Inc. subsidiary has entered into an agreement with Sanmina (SANM) to manufacture its mass spectrometry products.
|Over a month ago|
Astrotech files $250M mixed securities shelf 16:2403/0303/03/21
|Over a quarter ago|
Astrotech subsidiary exceeds $1M in purchase orders for Tracer 1000 » 07:2010/2810/28/20
Astrotech announced that…
Astrotech announced that its 1st Detect subsidiary has exceeded $1M in purchase orders and an additional $1M in future service & support commitments for its Tracer 1000 mass-spectrometry based explosives trace detector. Tracer 1000 units are currently deployed at multiple locations in eight countries across Europe & Asia, including numerous DHL locations.
Fly Intel: After-Hours Movers » 18:5810/2010/20/20
SNAP, CALX, TCS, USNA, HWC, WDFC, TXN, ASTC, OCX, NFLX, IRBT, NAVI, IBKR, THC, REPL, CWST, APTX
Check out this evening's…
Astrotech's BreathTech to develop COVID-19 screen » 16:0110/2010/20/20
The company states:…
The company states: "Astrotech Corporation's subsidiary, BreathTech Corporation announced today that it has signed a joint development agreement with Cleveland Clinic to explore leveraging Astrotech's BreathTest-1000 mass spectrometer to rapidly screen for COVID-19 or related indicators. The goal of the agreement is to develop a non-invasive device that will use breath samples to identify COVID-19 strains, with the potential to provide a low-cost, self-service screening option that could be deployed on a large-scale."
Astrotech files to sell common stock, no amount given 16:4807/0607/06/20